scholarly journals Ultrasound-based liver elastography: current results and future perspectives

2020 ◽  
Vol 45 (11) ◽  
pp. 3463-3472
Author(s):  
Cheng Fang ◽  
Paul S. Sidhu
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Chronic Liver Disease ◽  
Research Direction ◽  
Chronic Liver ◽  
Current Evidence ◽  
Diffuse Liver Disease ◽  
Disease Spectrum ◽  
Liver Elastography

Abstract Chronic liver disease affects 185 million population worldwide. It encompasses a heterogenous disease spectrum, but all can lead to the development of liver fibrosis. The degree of liver fibrosis is not only a prognosticator, but has also been used to guide the treatment strategy and to evaluate treatment response. Traditionally, staging of liver fibrosis is determined on histological analysis using samples obtained from an invasive liver biopsy. Ultrasound-based liver elastography is a non-invasive method of assessing diffuse liver disease in patients with known chronic liver disease. The use of liver elastography has led to a significant reduction in the number of liver biopsies performed to assess the severity of liver fibrosis and a liver biopsy is now reserved for only select sub-groups of patients. The aim of this review article is to discuss the key findings and current evidence for ultrasound-based elastography in diffuse liver disease as well as the technical challenges and to evaluate the potential research direction.

scholarly journals A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease

2019 ◽  
Vol 57 (1) ◽  
pp. 36-43
Author(s):  
Preya Janubhai Patel ◽  
Declan Connoley ◽  
Freya Rhodes ◽  
Ankur Srivastava ◽  
William Rosenberg
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Chronic Liver Disease ◽  
Clinical Utility ◽  
Chronic Liver ◽  
Biliary Cirrhosis ◽  
Alcoholic Fatty Liver ◽  
Functional Changes ◽  
Non Invasive

The rising incidence of chronic liver disease continues to be an increasing health burden. The morbidity and mortality associated with chronic liver disease typically occur in patients with advanced fibrosis. Hence, early identification of those at-risk is of vital importance to ensure appropriate ongoing management. Currently, tools for appropriate risk stratification remain limited. Increasing awareness of the limitations of liver biopsy has driven research into alternative non-invasive methods of fibrosis assessment including serological markers assessing functional changes. One such biomarker, the Enhanced Liver Fibrosis test, was initially validated in a cohort of 1021 patients with mixed aetiology chronic liver disease and shown to perform well. Since this pathfinder study, it has been independently validated in cohorts of hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, primary biliary cirrhosis and primary sclerosing cholangitis. In addition to performing well as a diagnostic tool, the Enhanced Liver Fibrosis test has been shown to outperform liver biopsy in prognostic studies and is the only non-invasive marker to do so. However, questions remain regarding the use of this test, particularly regarding the possible effect age and alcohol may have on test scores. This review examines the current literature published in relation to the Enhanced Liver Fibrosis test and its clinical utility and highlights areas requiring further study.

scholarly journals ANALISIS KING’S SCORE DI PENYAKIT HATI KRONIS BERDASARKAN FIBROSCAN

2018 ◽  
Vol 22 (2) ◽  
pp. 163
Author(s):  
Wira Wira ◽  
Amaliyah T. Lopa ◽  
Ibrahim Abdul Samad
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Chronic Liver Disease ◽  
Gold Standard ◽  
Chronic Liver ◽  
Operating Characteristics ◽  
Disease Etiology ◽  
Study Results ◽  
Auc Value

Chronic liver disease is a commonly found disease in Indonesia and remains a serious health problem. Chronic liver disease oftenprogresses to hepatic cirrhosis or hepatoma initiated by fibrotic process in liver. Liver biopsy result is a gold standard in determining theliver fibrosis degree, but it has some limitations. King’s Score is a non-invasive method that uses routine laboratory predictors relatedto liver fibrosis. Therefore, it is necessary to know the diagnostic value of King’s Score in determining the fibrosis degree of liver chronicdisease by using fibro scan as the gold standard in stead of biopsy. This study was a retrospective study with data collected from themedical records from the Medical Record Installation at the Dr. Wahidin Sudirohusodo General Hospital between January 2011 up toDecember 2013. The study results derived from 99 samples with Spearman correlation test showed a significant relationship between theKing’s Score and fibrosis degree of chronic liver disease (p=0.000 and r=0.651). The analysis of the receiver operating characteristics(ROC) indicated that in mild and moderate fibrosis the AUC value was too weak, whereas in heavy fibrosis the AUC value was 0.860,which was statistically very strong with a cut-off value of 7.15 and with a 80.6% sensitivity, and a 75.0% specificity, Positive PredictiveValue59.5%, Negative Predictive Value 89.5%. This meant that the King’s Score value of >7.15 could be used as a heavy fibrosis degreepredictor in chronic liver patients. Further studies are needed to analyze the King’s Score based on chronic liver disease etiology and usea liver biopsy as the gold standard in determining the degree of liver fibrosis.

Mac‐2 Binding Protein Glycan Isomer as non‐invasive tool to assess liver fibrosis in children with chronic liver disease

2021 ◽  
Author(s):  
Ola G Behairy ◽  
Soha A El‐Gendy ◽  
Dalia Y Ibrahim ◽  
Amira I Mansour ◽  
Ola S El‐Shimi
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Binding Protein ◽  
Chronic Liver ◽  
Non Invasive

scholarly journals Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients

2021 ◽  
Vol 14 ◽  
pp. 175628482110234
Author(s):  
Mario Romero-Cristóbal ◽  
Ana Clemente-Sánchez ◽  
Patricia Piñeiro ◽  
Jamil Cedeño ◽  
Laura Rayón ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Injury ◽  
Chronic Liver Disease ◽  
Critically Ill ◽  
Cox Regression ◽  
Chronic Liver ◽  
Cox Regression Analysis ◽  
Risk Of Death ◽  
The Impact

Background: Coronavirus disease (COVID-19) with acute respiratory distress syndrome is a life-threatening condition. A previous diagnosis of chronic liver disease is associated with poorer outcomes. Nevertheless, the impact of silent liver injury has not been investigated. We aimed to explore the association of pre-admission liver fibrosis indices with the prognosis of critically ill COVID-19 patients. Methods: The work presented was an observational study in 214 patients with COVID-19 consecutively admitted to the intensive care unit (ICU). Pre-admission liver fibrosis indices were calculated. In-hospital mortality and predictive factors were explored with Kaplan–Meier and Cox regression analysis. Results: The mean age was 59.58 (13.79) years; 16 patients (7.48%) had previously recognised chronic liver disease. Up to 78.84% of patients according to Forns, and 45.76% according to FIB-4, had more than minimal fibrosis. Fibrosis indices were higher in non-survivors [Forns: 6.04 (1.42) versus 4.99 (1.58), p < 0.001; FIB-4: 1.77 (1.17) versus 1.41 (0.91), p = 0.020)], but no differences were found in liver biochemistry parameters. Patients with any degree of fibrosis either by Forns or FIB-4 had a higher mortality, which increased according to the severity of fibrosis ( p < 0.05 for both indexes). Both Forns [HR 1.41 (1.11–1.81); p = 0.006] and FIB-4 [HR 1.31 (0.99–1.72); p = 0.051] were independently related to survival after adjusting for the Charlson comorbidity index, APACHE II, and ferritin. Conclusion: Unrecognised liver fibrosis, assessed by serological tests prior to admission, is independently associated with a higher risk of death in patients with severe COVID-19 admitted to the ICU.

108 ASSOCIATION OF GENES REGULATING VITAMIN D HOMEOSTASIS WITH VITAMIN D LEVELS AND LIVER FIBROSIS IN A COHORT OF PATIENTS WITH CHRONIC LIVER DISEASE

2011 ◽  
Vol 54 ◽  
pp. S48-S49
Author(s):  
F. Grünhage ◽  
K. Hochrath ◽  
M. Krawczyk ◽  
B. Obermayer-Pietsch ◽  
M. Trauner ◽  
...  
Keyword(s):  
Vitamin D ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Vitamin D Levels

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease

Gut ◽  
2010 ◽  
Vol 59 (9) ◽  
pp. 1245-1251 ◽  
Author(s):  
J. Parkes ◽  
P. Roderick ◽  
S. Harris ◽  
C. Day ◽  
D. Mutimer ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Clinical Outcomes ◽  
Chronic Liver
Sign in / Sign up

Export Citation Format

Share Document